anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To investigate the influence of adiponectin (APN) rs2241766 and rs1501299 polymorphisms on adiponectin levels and their association with metabolic syndrome (MetS).
METHODS: Analyzed two polymorphisms (rs2241766 and rs1501299) of the adiponectin gene (ADIPOQ) in 210 MetS patients and 102 control patients using the polymerase chain reaction-restriction fragment length polymorphism method and DNA sequencing technology.
RESULTS: The genotypes of the rs2241766 T/G and rs1501299 G/T polymorphism were significantly associated with serum APN levels in MetS patients. The ADIPOQ polymorphisms were associated with a risk of MetS when compared with that in healthy controls. TG and GG genotypes of rs2241766 were associated with a significantly elevated risk of MetS as compared with the TT genotype (OR = 1.32 and OR = 2.53). Subjects with the G allele appeared to have higher susceptibility to MetS than those with the T allele (OR = 2.21). In common with the findings for rs2241766, the rs1501299 GT and TT genotypes were associated with a significantly increased risk of MetS as compared with the GG genotype (OR = 1.51 and OR = 2.24). The susceptibility to MetS appeared to be higher in subjects with the T allele than in those with the G allele (OR = 1.88).
CONCLUSIONS: The occurrence of MetS may be associated with genetic variations at the rs2241766 and rs1501299 loci, especially in individuals with T to G mutations (rs2241766) and G to T mutations (rs1501299). These mutations may lead to decreased APN levels and a higher risk of developing MetS.
The present invention provides an inhalation-type pharmaceutical composition for Alzheimer's disease and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising rivastigmine hydrogen tartrate, donepezil hydrochloride, galantamine hydrobromide, memantine hydrochloride, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can provide the convenience of taking medicine and removing harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.
The development of an ischemic event, whether silent or painful, represents the cumulative impact of a sequence of pathophysiologic events. Each ischemic episode is initiated by an imbalance between myocardial oxygen supply and demand that may ultimately be manifested as angina pectoris. The ischaemic cascade is the concept that progressive myocardial oxygen supply-demand mismatch causes a consistent sequence of events, starting with metabolic alterations and followed sequentially by myocardial perfusion abnormalities, wall motion abnormalities, ECG changes, and angina. This concept would suggest that investigations that detect expressions of ischaemia earlier in the cascade should be more sensitive tests of ischaemia than those that detect expressions appearing later in the cascade.Visualization of a regional decrease in the systolic movement of the endocardium and a decrease in myocardial thickening are the main principles for the diagnosis of myocardial damage. However, the concept of ischaemic cascade is entirely based on clinical observations. It is not clear, which changes (mechanical or electrical) appear first during an episode of ischemia and which are prognostically more important. The objective of this study is to compare ischemic cascade towards ischemic constellation regarding beginning, duration and sequence of the electric, kinetic and haemodynamic signs of ischemia by FFR, icECG and wall motion abnormalities sign (M-sign - deformation and shortening of the wire tip) in patients with coronary bifurcation stenosis
Other: Early range of motion post-operative therapy protocol.Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
BACKGROUND: This study aimed to compare the muscle thickness and cross-sectional area (CSA), pain, disability, and fear of falling in patients with lumbar spinal stenosis (LSS) with and without balance problems.
METHODS: Sixty-four patients diagnosed with LSS by magnetic resonance imaging (MRI) were included in this cross-sectional study. The patients were divided into poor (n=31) and normal balance (n=33) groups according to the single leg standing test. Low back pain (Numeric rating scale), dynamic balance (Time up and go test), disability (Oswestry disability index) and fear of falling (International fall efficacy scale) in patients with LSS levels were evaluated. Lumbar (L4/5) multifidus muscle thickness and CSA were obtained from MRI images.
RESULTS: The poor balance group had a lower L4/5 multifidus thickness (p<0.05) and CSA (p<0.05) than the normal balance group. It was determined that an increase in left L4/5 multifidus muscle CSA was associated with decreased impaired balance (p=0.036). Also, a significant correlation was detected between static balance and muscle thickness and CSA (p<0.01). In addition, low back pain, disability, and fear of falling were significantly higher in LSS patients in the poor balance group (p<0.05).
CONCLUSION: Muscle atrophy and decrease in CSA are more common in LSS patients with poor balance. Decreased L4/5 multifidus muscle CSA may increase the risk of balance impairment. Also, LSS patients with poor balance are more likely to experience pain, disability, and fear of falling. Strategies to improve lumbar muscle stability, mass, and pain may reduce impaired balance in LSS.
Participants will be trained to perform a type of mind-body exercise that involves low intensity exercise and body movements similar to Tai Chi. Participants will be asked to exercise 2 times per day for 8 weeks.
The present invention discloses a method of preparing porous polymer microspheres by high voltage electrostatic anti-solvent process. Under the effect of high voltage electrostatic force, water-in-oil emulsion is discharged from an injection needle and is added dropwise to an anti-solvent. The organic solvent in the water-in-oil emulsion and the anti-solvent are miscible with each other, so that the polymer droplets takes the water emulsion droplets as nucleus and are cured and precipitated on surfaces of the nucleus, and the polymer microsphere structure containing pore-foaming agent water emulsion droplets is formed. The gas generated by ammonium hydrogen carbonate decomposition inside the microspheres because of emulsification opens holes on the surfaces of the polylactic acid microspheres to generate the porous structural microspheres. The present invention can be used for preparing drug carriers for inhaled pulmonary drug delivery. The experimental results show that: porous microspheres having a large geometric particle size can be prepared under ideal process parameters; the degree of sphericity is good, the surface is rough, the surface has a large number of pores of different sizes, and the interior is filled with through-hole structure; and increasing the input amount of ammonium hydrogen carbonate, the geometric particle size of the product can be significantly improved and the aerodynamic diameter can be reduced.
To reduce barriers to obtaining sunscreen and serve as cues to action, this group will be mailed during the months of May through September, a supply of SPF30 sunscreen lotion (known to prevent sun burning and skin cancer). The mailing will consist of large bottles of sunscreen and a small bottle that can be refilled and attached to their huge key rings that hang off of their belts.
Systems and methods are disclosed herein for processing ultrasound images to identify objects for diagnostic and/or interventional use. For instance, an ultrasound image of an anatomical structure may be received from a computing device of an ultrasound imaging system. The ultrasound image may be input to a machine learning model that is trained to identify a plurality of objects in ultrasound images of the anatomical structure. The plurality of objects may include anatomical features, disruptive features, and/or instruments. A prediction of one or more objects from the plurality of objects identified in the ultrasound image may be received as output of the machine learning model. An indication of the prediction may be provided to the computing device for display on a display of the ultrasound imaging system.
A particle-sized nanobody that can be inserted into at least one major physiological system of a mammal's body such as the blood stream or the gastro-intestinal track or other system. The nanobody of the present invention can remain in the system for a predetermined time to perform a predetermined task. nanobodies of the present invention can contain processors and memory and thus can be capable of performing tasks that require algorithmic or expert reasoning. The Nanobodies can also contain various sensors and can optionally have the ability to communicate with an external station or with each other. The Nanobodies can be designed to self-destruct either after a predetermined time or upon command from an external station. Once a nanobody has self-destructed, natural mechanisms of the body can remove the debris.
The invention describes a composition for use in disinfecting a surface for personal use, such as a public restroom facility or telephone. The composition and delivery of the composition provides for the placement of a thin layer of disinfectant which includes a acid-base indicator. The acid-base indicator disappears as the thin layer effects the germicidal activity of the disinfectant. The composition is also rapidly drying, so that the acid-base indicator disappears as well as the disinfecting composition leaving the surface dry. The invention also relates to use of the compositions in a lotion, such as a sunscreen. Use of the acid-base indicator provides a method to visualize where the lotion is applied by color, with the color then later dissipating.
PURPOSE: Thoracic epidural analgesia (TEA) is a well stablished technique for pain management in major thoracic and abdominal surgeries; however, it has considerable failure rates. Local anesthetic (LA) administration and subsequent assessment of sensory block through physical examination (e.g., decreased temperature perception determined via an LA temperature dissociation test [LATDT]) has been the historical standard for evaluation of thoracic epidural placement. Nevertheless, newer methods to objectively evaluate successful placement have recently been developed, e.g., the epidural electrical stimulation test (EEST) and epidural pressure waveform analysis (EWA). The purpose of this study was to evaluate the effectiveness of preoperative TEA catheter testing (LATDT, EEST, and EWA) on reducing TEA failure.
METHODS: After obtaining an institutional research ethics board approval for a retrospective study, we conducted a single-institution retrospective review on all TEAs performed between January 2016 and December 2021. Patients were assigned to one of four groups based on the performed test method to verify the placement of the TEA catheter: no test, LATDT, EEST, and EWA. A TEA was deemed successful if it provided bilateral dermatomal sensory block to ice test in the postoperative period, and was used for patient analgesia for at least 24 hr.
RESULTS: One thousand two hundred and forty-one patients submitted to preoperative TEA were included. Twenty-eight patients were excluded. Tested and untested epidurals had failure rates of 3.8% (95% confidence interval [CI], 1.8 to 6.2) and 11.5% (95% CI, 5.2 to 17.1), respectively (P < 0.001).
CONCLUSION: Objective preoperative testing after placement of thoracic epidurals was associated with a reduction in failure rates.
The present invention relates to a medicine for treating psoriasis, which is an oral traditional Chinese medicine preparation mainly used for treating psoriasis. The present invention is characterized in that a dose of traditional Chinese medicine is prepared from the raw materials of 20g of honeycomb, 5 centipedes, 30g of honeysuckle, 3g of pearl powder, 30g of raw sophora flower, 30g of unprocessed rehmannia root, 15g of cortex moutan, 25g of lalang grass rhizome, 15g of alkanet, 15g of red peony root, 25g of spatholobus stem and 80g of red date. The present invention has the functions of invigorating the kidney, nourishing blood, radically treating psoriasis, clearing heat, cooling blood, removing toxin, and mainly regulating the balance of yin-yang qi and blood of organisms. The present invention has the advantages of convenient administration, obvious effect of treatment action, and no toxic or side effect if the medicine for treating psoriasis is taken for a long time. The application of the medicine to treatment for 30 days is taken as a course of treatment, and the medicine for treating psoriasis takes the effect for patients in general within 3 weeks. The present invention is suitable for psoriasis caused by various reasons.
The main outcome will be pain acceptance. Other outcome measures will be global function (assessed with the Fibromyalgia Impact Questionnaire, FIQ), cost-effectiveness (evaluated by the Client Service Receipt Inventory, CSRI) and electroencephalographic cordance. The mediating variables included are anxiety and depression (assessed with the Hospital Anxiety and Depression scale, HADS) and pain (measured with an analog visual scale). A psychiatric interview will be administered to the participants to diagnose Posttraumatic Stress Disorder. Statistical analysis will be carried out for intention to treat, and using the method Last Observation Carried Forward. A Repeated Measures Mixed Model will be used to study the main outcome. All calculations will be made with two tails and a significance of 0.05.
Rufinamide, USP is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide, USP has the chemical name 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4carboxamide. It has a molecular formula of C 10H 8F 2N 4O and a molecular weight of 238.2. The drug substance is a white, crystalline powder. Rufinamide, USP is insoluble in water, slightly soluble in tetrahydrofuran and in methanol, and very slightly soluble in alcohol and in acetonitrile. 

Rufinamide is available for oral administration as a liquid containing rufinamide, USP at a concentration of 40 mg/mL. Inactive ingredients include anhydrous citric acid powder, hydrochloric acid, hydroxyethylcellulose, methylparaben, microcrystalline cellulose & carboxymethylcellulose sodium, natural and artificial orange flavor, poloxamer 188, potassium sorbate, propylene glycol, propylparaben, purified water, simethicone emulsion 30%, sodium hydroxide and sorbitol solution 70%.
BACKGROUND: Over the past 3 decades endovascular aortic aneurysm repair emerged as the primary approach for abdominal aortic aneurysm management, however the occurrence of endoleak following endograft implantation imposes a high toll on patients and hospitals alike. The early diagnosis and appropriate treatment of endoleaks is associated with better outcomes, which calls for more advanced imaging and a standardized approach for endoleak diagnosis and management following endovascular aortic aneurysm repair. Although conventional strategy with non-targeted deployment of coils and embolic material in the aneurysm sac is considered to be the standard approach in many hospitals, it may not prove to be a viable option, given that it affects any further follow-up imaging in the event of sub-optimal therapy and consequent recurrence.
METHODS: Based on our tertiary aortic referral center experience we summarize and describe strategies for optimal selection of various treatment approaches for Type-II Endoleak management including endovascular, percutaneous and laparoscopic approaches with particular focus on intraoperative image guidance techniques.
RESULTS: After failed conventional endovascular embolization attempt we recommend specific complex type II endoleak management approaches based on the location of the endoleak within the aneurysm sac along the x, y and z axis. A transabdominal or laparoscopic approach enable treatment in endoleaks located in the anterior portion of the sac. Endoleaks in the posterior portion of the sac could be treated using the transcaval or the translumbar approach, depending on whether the endoleak is situated on the left or the right side. Alternative strategies should be considered if patient anatomy does not allow for either transcaval or translumbar approach. The transgraft technique is reserved for endoleaks located in the cranial portion of the sac, while the perigraft approach could present a means of treatment for endoleaks situated in the caudal portion of the aneurysm sac.
CONCLUSION: We encourage establishing a patient specific treatment plan in accordance with individual anatomy based on cross sectional imaging modality (time resolved dynamic imaging in selected cases) and intraoperative image guidance to provide a safe and accurate endoleak localization and embolization for patients undergoing type II endoleak treatment.
Sensor in signal communication with at least one controller measure at least blood glucose levels, galvanic skin response microsiemens, heart rate, oxygen and temperature of a subject. At least one controller induces an individualized hypoglycemic condition within a predetermined non-homeostatic blood glucose level. Controllers may be in signal communication with one or more computing devices. The controller may also be a computing device. The system fluidly controls flow control devices to control delivery of at least insulin and glucose. The fluid control devices are in signal communication with at least one microprocessor having memory A controller controls the fluid control devices for at least insulin glucose, and a treatment cocktail to keep blood glucose level (BGL) within a target non-homeostatic hypoglycemic range.
DOSAGE MUST BE INDIVIDUALIZED. The initial dosage of Doxazosin mesylate in patients with hypertension and/or BPH is 1 mg given once daily in the a.m. or p.m. This starting dose is intended to minimize the frequency of postural hypotension and first-dose syncope associated with Doxazosin mesylate. Postural effects are most likely to occur between 2 and 6 hours after a dose. Therefore, blood pressure measurements should be taken during this time period after the first dose and with each increase in dose. If Doxazosin mesylate administration is discontinued for several days, therapy should be restarted using the initial dosing regimen.

Concomitant administration of Doxazosin mesylate with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension; therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking Doxazosin mesylate.
Cerebrovascular disease is the main cause of death and severe long-term disability worldwide. Antiplatelet drugs are the main drugs for ischemic stroke and TIA. Cyclooxygenase inhibitor acetylsalicylic acid (ASA) has always been the most widely studied antiplatelet therapy. The studies of acrates of aliscon body evaluated the efficacy and safety of ticagrelor monotherapy in preventing major vascular events in patients with AIS or TIA. The results showed that the number of patients with endpoint events in ticagrelor group was less than that in ASA group, However, it has not been proved that ticagrelor monotherapy is better than ASA. The purpose of this study is to prove that ticagrelor is better than ASA. The study will be designed as a randomized, double-blind, placebo-controlled, parallel grouping study and conducted in multiple centers to ensure the representation of multiple countries, races and races, so as to ensure that the results of the study can be widely applied.
Recently, improved understanding of the incretin effect on the pathophysiology of type 2 diabetes has led to development of new agent for hypoglycemic therapy. Vildagliptin is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that augments the active glucagon-like peptide(GLP)-1 concentration, increases insulin secretion and improves glucose tolerance. Vildagliptin has a similar glucose lowering effect, but lower hypoglycemic events, as compared to glimepiride. Vildagliptin could improve not only the mean glycemic control but also 24 hour glycemic fluctuation by restoring the physiologic pattern of insulin and glucagon secretion. Furthermore, decreased postprandial glycemic excursion might reduce the oxidative stress markers and improve endothelial dysfunction. Those effects might be amplified in Asian patients because of prominent early phase insulin secretory defects accompanied with relatively less degree of insulin resistance. In addition, GLP-1 and GLP-1 analogues exert direct beneficial effects on endothelium-dependent vasodilatation. Therefore DPP-4 inhibitors may directly improve endothelial dysfunction.

Based on this assumption, this research will focus on the effect of vildagliptin on glycemic variability, oxidative stress markers and endothelial cell function compared to long acting sulfonylurea glimepiride in type 2 diabetic patients with inadequate glycemic control on metformin.
Epidermal Growth Factor Receptor (EGFR) is overexpressed in Head and Neck Squamous Cell Carcinoma (HNSCC). EGFR pathway activation is associated with tumor growth, decreased apoptosis, and increased angiogenesis. These present a putative target for the use of EGFR inhibitors either in the form of small molecule inhibitors or monoclonal antibodies. Several studies have been advanced that suggest application of these targeted therapies show promising responses with little additional toxicity. The addition of EGFR monoclonal antibodies to radiation results in better response rates and locoregional control compared to radiation alone. Addition of EGFR monoclonal antibodies compared to chemotherapy alone also improves the response rates in patients with advanced HNSCC.

Nimotuzumab is a humanized chimeric monoclonal antibody specific to the extracellular domain of EGFR. Several studies are ongoing and demonstrate promising efficacy of Nimotuzumab as monotherapy and in combination with radiation in HNSCC, and in combination with chemoradiation in Nasopharyngeal Carcinoma. This phase II clinical trial examines the feasibility of EGFR inhibition using Nimotuzumab in combination with concurrent chemoradiotherapy in locally advanced unresectable HNSCC. Successful and safe incorporation of an EGFR monoclonal antibody into the concurrent chemoradiation paradigm used to treat locally advanced HNSCC will represent an important advance in the optimisation of treatment for this group of patients.